JP2017160212A5 - - Google Patents

Download PDF

Info

Publication number
JP2017160212A5
JP2017160212A5 JP2017074526A JP2017074526A JP2017160212A5 JP 2017160212 A5 JP2017160212 A5 JP 2017160212A5 JP 2017074526 A JP2017074526 A JP 2017074526A JP 2017074526 A JP2017074526 A JP 2017074526A JP 2017160212 A5 JP2017160212 A5 JP 2017160212A5
Authority
JP
Japan
Prior art keywords
insulin
per day
dapagliflozin
dosage
rosiglitazone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017074526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017160212A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017160212A publication Critical patent/JP2017160212A/ja
Publication of JP2017160212A5 publication Critical patent/JP2017160212A5/ja
Pending legal-status Critical Current

Links

JP2017074526A 2009-05-27 2017-04-04 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法 Pending JP2017160212A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18144209P 2009-05-27 2009-05-27
US61/181,442 2009-05-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015241499A Division JP2016104753A (ja) 2009-05-27 2015-12-10 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法

Publications (2)

Publication Number Publication Date
JP2017160212A JP2017160212A (ja) 2017-09-14
JP2017160212A5 true JP2017160212A5 (https=) 2018-03-01

Family

ID=42334303

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012513184A Withdrawn JP2012528170A (ja) 2009-05-27 2010-05-26 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法
JP2015241499A Pending JP2016104753A (ja) 2009-05-27 2015-12-10 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法
JP2017074526A Pending JP2017160212A (ja) 2009-05-27 2017-04-04 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2012513184A Withdrawn JP2012528170A (ja) 2009-05-27 2010-05-26 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法
JP2015241499A Pending JP2016104753A (ja) 2009-05-27 2015-12-10 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法

Country Status (5)

Country Link
US (1) US8685934B2 (https=)
EP (1) EP2435033A1 (https=)
JP (3) JP2012528170A (https=)
CN (2) CN106075451A (https=)
WO (1) WO2010138535A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sglt2阻害剤、dpp−iv阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
DK2396005T3 (da) 2009-02-13 2026-02-09 Boehringer Ingelheim Int Sglt2 hæmmer til at forbedre glykæmisk kontrol
EA020798B1 (ru) * 2009-09-30 2015-01-30 Бёрингер Ингельхайм Интернациональ Гмбх СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
PT2486029E (pt) 2009-09-30 2015-10-14 Boehringer Ingelheim Int Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo
UY32919A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
EP2498759B1 (en) 2009-11-13 2018-08-01 AstraZeneca AB Immediate release tablet formulations
ES2689107T3 (es) 2009-11-13 2018-11-08 Astrazeneca Ab Formulaciones de tabletas bicapa
EP2552442A1 (en) * 2010-03-30 2013-02-06 Boehringer Ingelheim International GmbH Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
WO2013095316A1 (en) * 2011-12-19 2013-06-27 Mahmut Bilgic Synergic combination comprising anti-diabetic agent
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
SG11201501510SA (en) * 2012-08-30 2015-04-29 Taisho Pharmaceutical Co Ltd Combinations of sglt2 inhibitors and antihypertensive drugs
EP3466431B1 (en) 2013-03-14 2023-11-15 MSD International GmbH Crystalline forms and methods for preparing sglt2 inhibitors
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP4678242A3 (en) 2013-04-18 2026-03-18 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
WO2014178040A1 (en) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
CN104496952B (zh) * 2014-11-28 2017-04-19 深圳翰宇药业股份有限公司 一种达格列净的合成方法
CR20170456A (es) 2015-04-07 2018-06-13 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapias combinadas
WO2017134615A1 (en) * 2016-02-03 2017-08-10 Dr. Reddy's Laboratories Limited Solid state forms of dasatinib and processes for their preparation
WO2017198177A1 (en) * 2016-05-20 2017-11-23 Center Laboratories, Inc. Method of treating hyperglycemia
KR20190084096A (ko) 2016-11-10 2019-07-15 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
WO2018167589A1 (en) 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Pharmaceutical composition comprising dapagliflozin
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
CN111405899B (zh) 2017-11-30 2025-05-16 爱杜西亚药品有限公司 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与sglt-2抑制剂的组合
US10639292B2 (en) 2018-04-20 2020-05-05 Center Laboratories, Inc. Method of treating hyperglycemia
AU2019278015B2 (en) 2018-05-31 2024-10-03 Hua Medicine (Shanghai) Ltd. Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof
JP2021528737A (ja) * 2018-06-14 2021-10-21 アストラゼネカ・ユーケイ・リミテッドAstraZeneca UK Limited グリフロジンナトリウム−グルコース共輸送2阻害剤医薬組成物を用いて血糖を下げるための方法
CN114650824A (zh) 2019-11-05 2022-06-21 雷斯韦洛吉克斯公司 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法
EP4082532A4 (en) * 2019-12-24 2024-03-13 Hanmi Pharm. Co., Ltd. COMPLEX FORMULATION WITH SITAGLITIN AND DAPAGLIFLOZIN AND METHOD FOR THE PRODUCTION THEREOF
IL297208A (en) * 2020-04-10 2022-12-01 Chinook Therapeutics Inc Treatment methods for diabetic kidney disease
CA3180674A1 (en) 2020-04-22 2021-10-28 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
KR102838283B1 (ko) * 2020-07-10 2025-07-25 한미약품 주식회사 시타글립틴 및 다파글리플로진을 포함하는 복합제제 및 그 제조방법
US12409186B2 (en) 2020-07-27 2025-09-09 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
US20230398137A1 (en) * 2020-10-30 2023-12-14 Resverlogix Corp. Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
CN114671839B (zh) * 2020-12-25 2024-01-09 天地恒一制药股份有限公司 达格列净的固体形式复合物及其制备方法与应用
US20250108065A1 (en) * 2022-01-26 2025-04-03 Astrazeneca Ab Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin
EP4493272A4 (en) * 2022-03-14 2026-02-25 Univ Virginia Patent Foundation Combination therapy of a sodium-glucose cotransporter inhibitor (SGLTI) and insulin for blood glucose regulation in type 1 diabetes
EP4385502A1 (en) * 2022-12-15 2024-06-19 Sanovel Ilac Sanayi Ve Ticaret A.S. A pharmaceutical formulation comprising metformin, pioglitazone and a sglt-2 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
IL149851A0 (en) 2002-05-26 2002-11-10 Yeda Res & Dev Resistin binding proteins, their preparation and use
TW200904405A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
WO2010045656A2 (en) * 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms

Similar Documents

Publication Publication Date Title
JP2017160212A5 (https=)
JP2011528713A5 (https=)
JP2011521940A5 (https=)
JP2013522194A5 (https=)
JP2018513188A5 (https=)
JP2009542702A5 (https=)
JP2016501841A5 (https=)
JP2009542699A5 (https=)
AU2016205138A1 (en) ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
JP2019515908A5 (https=)
JP2016528301A5 (https=)
KR20210005843A (ko) Glp1r 작용제의 치료적 용도
JP2013532658A5 (https=)
JP2008520544A5 (ja) 癌関連疲労の治療または予防のための医薬の製造への使用方法
JP2013541583A5 (https=)
JP2011503044A5 (https=)
FI4124339T3 (fi) Lääkkeenantojärjestelmiä ja -menetelmiä virtsarakon syövän hoitoon gemsitabiinilla
JP2019515909A5 (https=)
JP2018509419A5 (https=)
JPWO2021045159A5 (https=)
JP2010511039A5 (https=)
JP2020536121A5 (https=)
ES2656913T3 (es) Endrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes
JP2010500284A5 (https=)
JP2011500589A5 (https=)